3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasm, Residual
1
Burkitt Lymphoma
1
Interventions
fludarabine phosphate
2
fludarabine
2
blinatumomab
2
Cyclophosphamide
2
tislelizumab
1
tisagenlecleucel
1
obinutuzumab
1
Radiotherapy
1
Monatide (IMS 3015)
1
HMPL-013
1
Cetuximab
1
Blood Specimen Collection
1
Biological Assay
1
AP 1903 reagent
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
tisagenlecleucel
×
30 days
×
Clear all
NCT03876769
2026-06-02
CASSIOPEIA
Novartis
Phase 2
Active not recruiting
121 enrolled